查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1790481

美国抗生素抗药性市场规模、份额及趋势分析报告：按疾病、病原体、药物类别、作用机制、通路和细分市场预测，2025-2030 年

U.S. Antibiotic Resistance Market Size, Share, & Trends Analysis Report By Disease (cUTI, CDI), By Pathogen, By Drug Class, By Mechanism of Action, By Distribution Channel, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10个工作天内

价格

美国抗生素抗药性市场摘要

美国抗生素抗药性市场规模预计在 2024 年将达到 30.9 亿美元，预计到 2030 年将达到 39.9 亿美元，2025 年至 2030 年的复合年增长率为 4.4%。预计市场成长将受到抗生素滥用和过度使用增加的推动。

根据美国疾病管制与预防中心统计，美国每年报告的抗生素抗药性感染疾病超过 280 万例，导致 35,000 人死亡。此外，日益增长的公共卫生问题和对新型抗生素疗法的需求预计将推动市场成长。据世界卫生组织称，动物、人类和植物中抗生素的过度使用和滥用是导致抗药性病原体产生的主要原因。抗生素抗药性使感染疾病更难治疗，包括癌症化疗和置换术的医疗方法也更具风险。抗生素抗药性市场正在经历强劲增长，这得益于对能够对抗细菌对现有药物日益增长的抗药性的治疗方法的迫切需求。

当您感染疾病抗生素抗药性细菌时，病情会变得更加难以控制，因为目前有效治疗感染疾病的抗生素种类越来越少。此外，这些抗药性细菌也会传播给其他人，增加感染扩散的风险。在极少数情况下，可用的治疗方案可能非常有限。

目录

第一章调查方法与范围

第二章执行摘要

第三章美国抗生素抗药性市场变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析

第四章美国抗生素抗药性市场分析工具

  • 产业分析-波特五力分析
    • 供应商权力
    • 购买力
    • 替代威胁
    • 新进入者的威胁
    • 竞争对手之间的竞争
  • PESTEL分析
    • 政局
    • 技术格局
    • 经济情势
  • 美国抗生素抗药性市场：渠道分析

第五章美国抗生素抗药性市场：疾病估计与趋势分析

  • 疾病细分仪表板
  • 美国抗生素抗药性市场：疾病趋势分析
  • 美国抗生素抗药性市场规模与趋势分析（按疾病，2018-2030 年）
  • CUTI
  • CDI
  • ABSSSI
  • HABP
  • CABP
  • cIAI
  • BSI

第六章美国抗生素抗药性市场：病原体估计和趋势分析

  • 病原体细分仪表板
  • 美国抗生素抗药性市场：病原体变异分析
  • 美国抗生素抗药性市场规模及趋势分析（按病原体，2018-2030）
  • 大肠桿菌
  • 肺炎克雷伯菌
  • 铜绿假单胞菌
  • 金黄色葡萄球菌
  • A. 鲍曼
  • 肺炎球菌
  • 流感细菌
  • CDI
  • 屎肠球菌

第七章美国抗生素抗药性市场：药物类别估计与趋势分析

  • 药品类别细分仪表板
  • 美国抗生素抗药性市场：药物类别变异分析
  • 美国抗生素抗药性市场规模及趋势分析（依药物类别，2018-2030）
  • Oxazolidinone
  • 醣肽
  • 四环霉素
  • 联合治疗
  • 头孢菌素类
  • 其他的

第八章美国抗生素抗药性市场：作用机制评估与趋势分析

  • 作用机制细分仪表板
  • 美国抗生素抗药性市场：作用机制变异分析
  • 美国抗生素抗药性市场规模及趋势分析（按作用机制，2018-2030）
  • 蛋白质合成抑制剂
  • 细胞壁合成抑制剂
  • RNA合成抑制剂
  • DNA合成抑制剂
  • 其他的

第九章美国抗生素抗药性市场：通路评估与趋势分析

  • 分销通路细分仪表板
  • 美国抗生素抗药性市场：分布波动分析
  • 美国抗生素抗药性市场规模及通路趋势分析（2018-2030）
  • 零售药局
  • 医院药房
  • 网路药局

第十章 竞争格局

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商格局
    • Key company heat map analysis, 2024
  • 公司简介
    • Melinta Therapeutics
    • Merck &Co., Inc.
    • Melinta Therapeutics LLC
    • Theravance Biopharma.
    • Paratek Pharmaceuticals, Inc.
    • Seres Therapeutics
    • AbbVie Inc.
Product Code: GVR-4-68040-664-4

U.S. Antibiotic Resistance Market Summary

The U.S. antibiotic esistance market size was estimated at USD 3.09 billion in 2024 and is projected to reach USD 3.99 billion by 2030, growing at a CAGR of 4.4% from 2025 to 2030. The market is expected to grow, driven by the rising misuse and overuse of antibiotics.

According to the CDC, more than 2.8 million antimicrobial-resistant infections are reported every year in the U.S., leading to 35,000 deaths. Moreover, the rise of public health concerns and the need for new antibiotic therapies are expected to drive market growth. According to the WHO, the overuse and misuse of antibiotics in animals, humans, and plants are the main reasons for the development of drug-resistant pathogens. Antibiotic resistance makes infections hard to treat and makes medical treatments, including cancer chemotherapy and surgeries such as cesarean sections and hip replacements, riskier. The market for antibiotic therapies is witnessing strong growth, driven by the urgent demand for treatments that can counteract rising resistance to existing drugs.

When a person contracts an infection caused by antibiotic-resistant bacteria, managing the illness becomes more challenging because fewer antibiotics can effectively treat the infection. In addition, these resistant bacteria can be transmitted to others, increasing the risk of wider spread. There are some rare instances where very few treatment options may be available.

U.S. Antibiotic Resistance Market Report Segmentation

This report forecasts revenue at the country level and analyzes the latest industry trends in each sub-segment from 2018 to 2030. For this study, Grand View Research has segmented the U.S. Antibiotic Resistance Market report based on disease, pathogen, drug class, mechanism of action, and distribution channel:

  • Disease Outlook (Revenue in USD Million, 2018 - 2030)
  • cUTI
  • CDI
  • ABSSSI
  • HABP
  • CABP
  • cIAI
  • BSI
  • Pathogen Outlook (Revenue in USD Million, 2018 - 2030)
  • E. coli
  • klebsiella pneumoniae
  • P. aeruginosa
  • S. aureus
  • baumannii
  • Strep. Pneumoniae
  • H. influenzae
  • CDI
  • Enterococcus fecium
  • Drug Class Outlook (Revenue in USD Million; 2018 - 2030)
  • Oxazolidinones
  • Lipoglycopeptides
  • Tetracyclines
  • Combination therapies
  • Cephalosporins
  • Others
  • Mechanism of Action Outlook (Revenue in USD Million; 2018 - 2030)
  • Protein Synthesis Inhibitors
  • Cell Wall Synthesis Inhibitors
  • RNA Synthesis Inhibitors
  • DNA Synthesis Inhibitors
  • Others
  • Distribution Channel Outlook (Revenue in USD Million; 2018 - 2030)
  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Disease
    • 1.2.2. Pathogen
    • 1.2.3. Drug Class
    • 1.2.4. Mechanism of Action
    • 1.2.5. Distribution Channel
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Disease outlook
    • 2.2.2. Pathogen outlook
    • 2.2.3. Drug Class outlook
    • 2.2.4. Mechanism of Action
    • 2.2.5. Distribution Channel
  • 2.3. Competitive Insights

Chapter 3. U.S. Antibiotic Resistance Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis

Chapter 4. U.S. Antibiotic Resistance Market Analysis Tools

  • 4.1. Industry Analysis - Porter's
    • 4.1.1. Supplier power
    • 4.1.2. Buyer power
    • 4.1.3. Substitution threat
    • 4.1.4. Threat of new entrant
    • 4.1.5. Competitive rivalry
  • 4.2. PESTEL Analysis
    • 4.2.1. Political landscape
    • 4.2.2. Technological landscape
    • 4.2.3. Economic landscape
  • 4.3. U.S. Antibiotic Resistance Market: Pipeline Analysis

Chapter 5. U.S. Antibiotic Resistance Market: Disease Estimates & Trend Analysis

  • 5.1. Disease Segment Dashboard
  • 5.2. U.S. Antibiotic Resistance Market: Disease Movement Analysis
  • 5.3. U.S. Antibiotic Resistance Market Size & Trend Analysis, by Disease, 2018 to 2030 (USD Million)
  • 5.4. cUTI
    • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. CDI
    • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. ABSSSI
    • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. HABP
    • 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. CABP
    • 5.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9. cIAI
    • 5.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.10. BSI
    • 5.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Antibiotic Resistance Market: Pathogen Estimates & Trend Analysis

  • 6.1. Pathogen Segment Dashboard
  • 6.2. U.S. Antibiotic Resistance Market: Pathogen Movement Analysis
  • 6.3. U.S. Antibiotic Resistance Market Size & Trend Analysis, by Pathogen, 2018 to 2030 (USD Million)
  • 6.4. E. coli
    • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. klebsiella pneumoniae
    • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. P. aeruginosa
    • 6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. S. aureus
    • 6.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. A. baumannii
    • 6.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. Strep. Pneumoniae
    • 6.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.10. H. influenzae
    • 6.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.11. CDI
    • 6.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.12. Enterococcus fecium
    • 6.12.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. U.S. Antibiotic Resistance Market: Drug Class Estimates & Trend Analysis

  • 7.1. Drug Class Segment Dashboard
  • 7.2. U.S. Antibiotic Resistance Market: Drug Class Movement Analysis
  • 7.3. U.S. Antibiotic Resistance Market Size & Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
  • 7.4. Oxazolidinones
    • 7.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 7.5. Lipoglycopeptides
    • 7.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Tetracyclines
    • 7.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Combination therapies
    • 7.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Cephalosporins
    • 7.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. Others
    • 7.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. U.S. Antibiotic Resistance Market: Mechanism of Action Estimates & Trend Analysis

  • 8.1. Mechanism of Action Segment Dashboard
  • 8.2. U.S. Antibiotic Resistance Market: Mechanism of Action Movement Analysis
  • 8.3. U.S. Antibiotic Resistance Market Size & Trend Analysis, by Mechanism of Action, 2018 to 2030 (USD Million)
  • 8.4. Protein Synthesis Inhibitors
    • 8.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 8.5. Cell Wall Synthesis Inhibitors
    • 8.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. RNA Synthesis Inhibitors
    • 8.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. DNA Synthesis Inhibitors
    • 8.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8. Others
    • 8.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. U.S. Antibiotic Resistance Market: Distribution Channel Estimates & Trend Analysis

  • 9.1. Distribution Channel Segment Dashboard
  • 9.2. U.S. Antibiotic Resistance Market: Distribution Movement Analysis
  • 9.3. U.S. Antibiotic Resistance Market Size & Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 9.4. Retail Pharmacies
    • 9.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 9.5. Hospital Pharmacies
    • 9.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6. Online Pharmacies
    • 9.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 10.2. Company/Competition Categorization
  • 10.3. Vendor Landscape
    • 10.3.1. Key company heat map analysis, 2024
  • 10.4. Company Profiles
    • 10.4.1. Melinta Therapeutics
      • 10.4.1.1. Company overview
      • 10.4.1.2. Financial performance
      • 10.4.1.3. Product benchmarking
      • 10.4.1.4. Strategic initiatives
    • 10.4.2. Merck & Co., Inc.
      • 10.4.2.1. Company overview
      • 10.4.2.2. Financial performance
      • 10.4.2.3. Product benchmarking
      • 10.4.2.4. Strategic initiatives
    • 10.4.3. Melinta Therapeutics LLC
      • 10.4.3.1. Company overview
      • 10.4.3.2. Financial performance
      • 10.4.3.3. Product benchmarking
      • 10.4.3.4. Strategic initiatives
    • 10.4.4. Theravance Biopharma.
      • 10.4.4.1. Company overview
      • 10.4.4.2. Financial performance
      • 10.4.4.3. Product benchmarking
      • 10.4.4.4. Strategic initiatives
    • 10.4.5. Paratek Pharmaceuticals, Inc.
      • 10.4.5.1. Company overview
      • 10.4.5.2. Financial performance
      • 10.4.5.3. Product benchmarking
      • 10.4.5.4. Strategic initiatives
    • 10.4.6. Seres Therapeutics
      • 10.4.6.1. Company overview
      • 10.4.6.2. Financial performance
      • 10.4.6.3. Product benchmarking
      • 10.4.6.4. Strategic initiatives
    • 10.4.7. AbbVie Inc.
      • 10.4.7.1. Company overview
      • 10.4.7.2. Financial performance
      • 10.4.7.3. Product benchmarking
      • 10.4.7.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 U.S. Antibiotic Resistance market, by Disease, 2018 - 2030 (USD Million)
  • Table 3 U.S. Antibiotic Resistance market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 4 U.S. Antibiotic Resistance market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 5 U.S. Antibiotic Resistance market, by Mechanism of Action, 2018 - 2030 (USD Million)
  • Table 6 U.S. Antibiotic Resistance market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. antibiotic resistance market: market outlook
  • Fig. 10 U.S. antibiotic resistance competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 U.S. antibiotic resistance market driver impact
  • Fig. 16 U.S. antibiotic resistance market restraint impact
  • Fig. 17 U.S. antibiotic resistance market strategic initiatives analysis
  • Fig. 18 U.S. antibiotic resistance market: Disease movement analysis
  • Fig. 19 U.S. antibiotic resistance market: Disease outlook and key takeaways
  • Fig. 20 cUTI market estimates and forecast, 2018 - 2030
  • Fig. 21 CDI estimates and forecast, 2018 - 2030
  • Fig. 22 ABSSSI market estimates and forecast, 2018 - 2030
  • Fig. 23 HABP market estimates and forecast, 2018 - 2030
  • Fig. 24 CABP market estimates and forecast, 2018 - 2030
  • Fig. 25 cIAI estimates and forecast, 2018 - 2030
  • Fig. 26 BSI estimates and forecast, 2018 - 2030
  • Fig. 27 U.S. antibiotic resistance market: Pathogen movement analysis
  • Fig. 28 U.S. antibiotic resistance market: Pathogen outlook and key takeaways
  • Fig. 29 E. coli market estimates and forecasts, 2018 - 2030
  • Fig. 30 klebsiella pneumoniae market estimates and forecasts, 2018 - 2030
  • Fig. 31 P. aeruginosa market estimates and forecasts, 2018 - 2030
  • Fig. 32 S. aureus market estimates and forecasts, 2018 - 2030
  • Fig. 33 A. baumannii market estimates and forecasts, 2018 - 2030
  • Fig. 34 Strep. Pneumoniae market estimates and forecasts, 2018 - 2030
  • Fig. 35 H. influenzae market estimates and forecasts, 2018 - 2030
  • Fig. 36 CDI market estimates and forecasts, 2018 - 2030
  • Fig. 37 Enterococcus fecium market estimates and forecasts, 2018 - 2030
  • Fig. 38 U.S. antibiotic resistance market: Drug class movement analysis
  • Fig. 39 U.S. antibiotic resistance market: Drug class outlook and key takeaways
  • Fig. 40 Oxazolidinones market estimates and forecasts, 2018 - 2030
  • Fig. 41 Lipoglycopeptides market estimates and forecasts, 2018 - 2030
  • Fig. 42 Tetracyclines market estimates and forecasts, 2018 - 2030
  • Fig. 43 Combination therapies market estimates and forecasts, 2018 - 2030
  • Fig. 44 Cephalosporins market estimates and forecasts, 2018 - 2030
  • Fig. 45 Others market estimates and forecasts, 2018 - 2030
  • Fig. 46 U.S. antibiotic resistance market: Mechanism of action movement analysis
  • Fig. 47 U.S. antibiotic resistance market: Mechanism of action outlook and key takeaways
  • Fig. 48 Protein synthesis inhibitors market estimates and forecasts, 2018 - 2030
  • Fig. 49 Cell wall synthesis inhibitors market estimates and forecasts, 2018 - 2030
  • Fig. 50 RNA synthesis inhibitors market estimates and forecasts, 2018 - 2030
  • Fig. 51 DNA synthesis inhibitors market estimates and forecasts, 2018 - 2030
  • Fig. 52 Others market estimates and forecasts, 2018 - 2030
  • Fig. 53 U.S. antibiotic resistance market: Distribution channel movement analysis
  • Fig. 54 U.S. antibiotic resistance market: Distribution channel outlook and key takeaways
  • Fig. 55 Retail pharmacies market estimates and forecasts, 2018 - 2030
  • Fig. 56 Hospital pharmacies market estimates and forecasts, 2018 - 2030
  • Fig. 57 Online pharmacies market estimates and forecasts, 2018 - 2030